Minerva Neurosciences (NERV) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Executive summary
Annual meeting scheduled for June 3, 2026, with virtual participation available to shareholders.
Shareholders are encouraged to review proxy materials and vote by June 2, 2026.
Voting matters and shareholder proposals
Election of two Class III directors to serve until the 2029 annual meeting, with board recommending both nominees.
Proposal to amend the charter to allow officer exculpation under Delaware law.
Proposal to amend the charter to eliminate the exclusive forum provision.
Advisory vote on executive compensation and on the preferred frequency of future say-on-pay votes.
Ratification of Deloitte & Touche LLP as independent auditor for fiscal year ending December 31, 2026.
Board of directors and corporate governance
Board recommends all proposals, including director nominees and charter amendments.
Proxies are authorized to vote on other business that may arise at the meeting.
Latest events from Minerva Neurosciences
- Roluperidone targets negative symptoms in schizophrenia, with pivotal data expected in 2027.NERV
Jefferies Global Healthcare Conference 20264 Jun 2026 - All proposals, including director elections and governance amendments, were approved.NERV
AGM 20263 Jun 2026 - Roluperidone advances as the first late-stage therapy for negative symptoms of schizophrenia.NERV
Corporate presentation3 Jun 2026 - Net loss rose to $125.4M on non-cash warrant expenses as Phase 3 roluperidone trial launched.NERV
Q1 20265 May 2026 - Roluperidone shows promise for negative symptoms in schizophrenia, with pivotal trial results due next year.NERV
Stifel 2026 Virtual CNS Forum5 May 2026 - Six key proposals, including governance and compensation changes, are up for vote at the 2026 meeting.NERV
Proxy filing23 Apr 2026 - Six key proposals, including director elections and charter amendments, headline the 2026 annual meeting.NERV
Proxy filing10 Apr 2026 - Registering up to $200M in securities to fund CNS drug development and corporate growth.NERV
Registration Filing11 Mar 2026 - 2025 net loss driven by non-cash charges; Phase 3 trial for roluperidone set for Q2 2026.NERV
Q4 202511 Mar 2026